Functional studies of tyrosine hydroxylase missense variants reveal distinct patterns of molecular defects in dopa-responsive dystonia by Fossbakk, Agnete et al.
RESEARCH ARTICLE
OFFICIAL JOURNAL
www.hgvs.org
Functional Studies of Tyrosine Hydroxylase Missense
Variants Reveal Distinct Patterns of Molecular Defects in
Dopa-Responsive Dystonia
Agnete Fossbakk,1,2 Rune Kleppe,1,2 Per M. Knappskog,2,3,4 Aurora Martinez,1,2 and Jan Haavik1,2∗
1Department of Biomedicine, University of Bergen, Bergen, Norway; 2K. G. Jebsen Centre for Research on Neuropsychiatric Disorders, University
of Bergen, Bergen, Norway; 3Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway; 4Department
of Clinical Medicine, University of Bergen, Bergen, Norway
Communicated by Mireille Claustres
Received 1 January 2014; accepted revised manuscript 10 April 2014.
Published online 21 April 2014 in Wiley Online Library (www.wiley.com/humanmutation). DOI: 10.1002/humu.22565
ABSTRACT: Congenital tyrosine hydroxylase deficiency
(THD) is found in autosomal-recessive Dopa-responsive
dystonia and related neurological syndromes. The clin-
ical manifestations of THD are variable, ranging from
early-onset lethal disease to mild Parkinson disease-like
symptoms appearing in adolescence. Until 2014, approx-
imately 70 THD patients with a total of 40 different
disease-related missense mutations, five nonsense muta-
tions, and three mutations in the promoter region of the
tyrosine hydroxylase (TH) gene have been reported. We
collected clinical and biochemical data in the literature for
all variants, and also generated mutant forms of TH vari-
ants previously not studied (N = 23). We compared the
in vitro solubility, thermal stability, and kinetic properties
of the TH variants to determine the cause(s) of their im-
paired enzyme activity, and found great heterogeneity in
all these properties among the mutated forms. Some TH
variants had specific kinetic anomalies and phenylalanine
hydroxylase, and Dopa oxidase activities were measured
for variants that showed signs of altered substrate bind-
ing. p.Arg233His, p.Gly247Ser, and p.Phe375Leu had
shifted substrate specificity from tyrosine to phenylalanine
and Dopa, whereas p.Cys359Phe had an impaired activity
toward these substrates. The new data about pathogenic
mechanisms presented are expected to contribute to
develop individualized therapy for THD patients.
Hum Mutat 35:880–890, 2014. Published 2014 Wiley Periodi-
cals, Inc.∗
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Introduction
Tyrosine hydroxylase (TH; MIM #191290) is an aromatic amino
acid hydroxylase (AAAH) that catalyzes the rate-limiting step in
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the synthesis of the catecholamines, dopamine, adrenaline, and
noradrenaline. The enzyme is structurally and functionally related
to phenylalanine hydroxylase (PAH; MIM #612349) and trypto-
phan hydroxylase 1 and 2 (TPH1; MIM #191060, TPH2; MIM
#607478). All AAAHs are dependent on the cofactor tetrahydro-
biopterin (BH4), molecular oxygen, and ferrous iron to hydroxylate
their substrate. In addition to the hydroxylation of tyrosine (L-Tyr)
to form dihydroxyphenylalanine (L-Dopa, TH can catalyze the hy-
droxylation of phenylalanine (L-Phe) to L-Tyr [Fitzpatrick, 1999],
and the oxidation of L-Dopa [Haavik, 1997] (Fig. 1).
In the brain, TH is mainly expressed in dopaminergic neurons in
the ventral tegmental area and substantia nigra pars compacta, and
in the noradrenergic neurons of the locus coeruleus. In the periphery,
TH is mainly found in sympathetic neurons and in the adrenal
medulla [Nagatsu and Ichinose, 1991]. In humans, a single TH gene
encodes four main isoforms of TH protein (hTH), generated by
alternative splicing of pre-mRNA [Grima et al., 1987]. Alternative
splicing of mRNA results from the use of two donor sites in
exon 1 and inclusion/exclusion of exon 2. Isoform 1 (hTH1) has
no insertion and isoform 4 (hTH4) has the longest insertion of
31 additional amino acid residues. The nomenclature of missense
and nonsense mutations in the TH gene in the literature refers to
the corresponding amino acid substitution of the full-length form
of the enzyme (hTH4). However, in some previous studies of TH
variants, the nomenclature of the mutations has been based on
hTH1 [Knappskog et al., 1995; Ludecke et al., 1996; Royo et al.,
2005; Calvo et al., 2010]. The alternative splicing affects the enzyme
regulation by phosphorylation, but only modest differences in the
catalytic properties of the isoforms have been reported [Haavik
et al., 1991; Nasrin et al., 1994; Gordon et al., 2009]. hTH1 is most
abundant, and is also the isoform studied most commonly in vitro
as a recombinant enzyme.
Mutations in the TH gene are found in patients with tyrosine
hydroxylase deficiency (THD; MIM #605407), which is associated
with autosomal-recessive Dopa-responsive dystonia and related
neurological syndromes with predominantly motor symptoms
[Willemsen et al., 2010]. TheTHDpatients reported in the literature
have symptoms ranging from mild Parkinson´s disease (PD)-like
characteristics to severe neurodegenerative encephalopathy.
Willemsen et al. (2010) reviewed the clinical and biochemical data
on 36 patients and the literature describing phenotypes and geno-
types of THD. They proposed to categorize the patients into two
subgroups, THD typeA andB, based on clinical features. TypeAwas
defined as a progressive extrapyramidal movement disorder with
onset in infancy or childhood. Type B is a more severe, complex en-
cephalopathy with onset in the neonatal period or early infancy. The
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Figure 1. Enzymatic activities of tyrosine hydroxylase. In addition to the hydroxylation of L-Tyr to form L-Dopa, TH can catalyze the hydroxylation
of L-Phe to L-Tyr, and the oxidation of L-Dopa.
majority of patients belong to the typeA category, and these patients
generally respond well to treatment with L-Dopa. In contrast,
patients who suffer from type B THD are often poor responders to
substitution treatment with L-Dopa, and are possibly more prone to
L-Dopa-induced dyskinesias [Pons et al., 2013]. Even within these
groups, there is great variation in phenotype of patients with muta-
tions in the TH gene. To date, no correlation between genotype and
phenotype has been established. Homozygosity of the p.Arg233His
mutation has been found in six type A and three type B patients. The
p.Leu236Pro mutation occurred homozygously in one type A and
two type B patients. However, all patients with at least one promoter
mutation had the type A THD [Willemsen et al., 2010]. As all
reported missense mutations of the TH gene in THD affect amino
acid residues that are present in all isoforms of TH (hTH1-4), their
effects on protein function should be evident in all four isoforms.
So far, seven of the reported missense mutations in the TH gene
have been characterized at the protein level. Thus, reduced sta-
bility and/or activity was found for hTH1 p.Leu205Pro [Ludecke
et al., 1996], p.Gln381Lys (corresponding to p.Leu236Pro and
p.Gln412Lys in hTH4) [Knappskog et al., 1995], p.Thr245Pro,
p.Thr283Met, p.Arg306His, p.Thr463Met (corresponding to
p.Thr276Pro, p.Thr314Met, p.Arg337His, p.Thr494Met in TH4)
[Royo et al., 2005], and most recently the TH mutant p.Arg202His
(corresponding to p.Arg233His in TH4) [Calvo et al., 2010], which
is the most common mutation found in THD patients [Willemsen
et al., 2010].
The aim of the present study was to perform a molecular char-
acterization and genotype–phenotype analyses of all protein coding
variants reported in THD where clinical data are available. In ad-
dition to the seven missense mutations characterized biochemically
earlier [Knappskog et al., 1995; Ludecke et al., 1996; Royo et al., 2005;
Calvo et al., 2010], we characterized the enzymatic and biophysical
properties ofproteins carrying eachof the21THmissensemutations
and one nonsense mutation that have been reviewed [Willemsen
et al., 2010], and a recently described Norwegian missense muta-
tion, that is, p.Arg441Pro [Haugarvoll and Bindoff, 2011].
Here, we report remarkable variable effects of the disease muta-
tions on TH, affecting the solubility, stability, activity, and substrate
specificity of the enzyme. This novel knowledge about themolecular
mechanism underlying disease progression has potential implica-
tions for future diagnosis and management of THD.
Materials and Methods
Materials
6R-tetrahydrobiopterin (BH4) was purchased from Dr. B. Schir-
cks Laboratories (Jona, Switzerland). BL(21)D3pLysS Escherichia
coli, andTheAmplex R© RedHydrogen Peroxide/Peroxidase Assay kit
were purchased from InvitrogenTM (Thermo Fisher Scientific Inc.,
Waltham, MA, US). Complete Protease inhibitor cocktail, EDTA-
free and Lysis-B reagent were obtained from Roche (Mannheim,
Germany). Other reagents for the TH activity assay were of ana-
lytical grade and purchased from Sigma (St. Louis, MO), unless
otherwise stated.
Construction of Plasmids
Mutations were introduced into the wild-type (wt)-hTH1 cDNA
on thepET3a-hTH1vector [LeBourdelles et al., 1991]byPCR-based
mutagenesis using the QuikChange mutagenesis kit (Stratagene, La
Jolla, CA). NCBI Reference Sequence: NM 199292.2. Nucleotide
numbering uses +1 as the A of the ATG translation initiation codon
in the reference sequence.Mutagenesiswas carriedoutusingprimers
from InvitrogenTM (Supp. Table S1). Introduction of the correct
mutation and exclusion of other mutations were verified by Sanger
sequencing of the whole coding region.
Expression and Purification of Proteins Expressed in E. coli
Recombinant wt human TH, isoform 1 (hTH1), and the mutant
TH were expressed in BL(21)D3pLysS E. coli (InvitrogenTM). The
bacteria were grown at 37°C in LB medium containing 50 μg ml–1
of ampicillin and 34 μg ml–1 of chloramphenicol. The expression of
T7 polymerase was induced at OD600 nm = 0.8 by addition of 1 mM
isopropyl 6-D-thiogalactopyranoside. Temperature was decreased
to 25°C after induction, and the bacteria were harvested after 6-h
incubation. Bacteria pellets were kept at –20°C until purification.
Bacteria (from 1 l of culture) were diluted in 20 mM Tris/HCl
pH 7.6, containing 5% sucrose (w/v), 1 mM dithiothreitol (DTT),
1mMEDTA, 0.1mMphenylmethylsulfonyl fluoride, and one tablet
Complete Protease inhibitor cocktail, EDTA-free (Roche)/25 ml,
and disrupted by passage through a French press (type FA-073; SLM
Instruments, Urbana, IL) at 69 MPa. The lysate was centrifuged
at 12,000g for 20 min, and the supernatant used for purification
by heparin sepharose chromatography [Haavik et al., 1991]. The
purified enzymes were concentrated and stored in liquid nitrogen
until used.
Solubility of TH, wt, and Mutants
hTH1- and THD-associatedmutants were expressed as described
above and bacteria were harvested by centrifugation at 4,000g for
20 min at 4°C. Cell pellets (5 ml cultures) were resuspended in
Lysis-B reagent containing Complete Protease inhibitor cocktail,
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EDTA-free following the protocol provided by the manufacturer
(Roche). Aliquots of the extracts were centrifuged at 10,000g for
20min. Proteins in the soluble and insoluble fractionswere analyzed
by SDS-PAGE, with quantification of the bands by Quantity One
software [McKinney et al., 2004].
Assays of Enzyme Activity and Data Analysis
TH activity was assayed at 25°C in a standard reaction mixture
containing 200 μM BH4, 2 mM DTT, 10 μM Fe(II) ammonium
sulfate, 0.1 mg ml–1 catalase, and 50 μM tyrosine (L-Tyr) in 40 mM
Na-Hepes pH 7.0. The enzyme was diluted to 10 μM subunit con-
centration (0.56 mg ml–1) in buffer-containing 10 μM Fe(II) am-
monium sulfate and 0.5 mg ml–1 BSA and preincubated on ice. The
formation of Dopa wasmeasured byHPLCwith fluorimetric detec-
tion [Haavik and Flatmark, 1980]. PAH activity of wt and mutant
TH was assayed in the same way as TH activity, with phenylalanine
(L-Phe) replacing L-Tyr. L-Tyr formation was detected by HPLC.
L-Dopa oxidase activity of wt and mutant TH was assayed by a
radiochemical method as previously described [Haavik, 1997]. To
determine the enzyme kinetic parameters of wt andmutant TH, the
concentration of BH4 was varied (0–500 μM), keeping L-Tyr levels
constant (50μM), or L-Tyr concentrationswere varied (0–200μM),
and BH4 levels were kept constant (200 μM). The Km values for
L-Phe were determined using 0–300 μM L-Phe and 200 μM BH4.
We used nonlinear regression curve fitting in SigmaPlot (version
9.0; Systat Software, Inc., San Jose, CA) to determine the kinetic pa-
rameters for TH, wt, and mutants, using either a simple Michaelis–
Menten (MM) equation or MM with substrate inhibition (Eq. 1).
To obtain a robust comparison between mutant proteins, the num-
ber of parameters was kept at a minimum. Simple MM equation
was used if no clear evidence for substrate inhibition was found in
the substrate range used here (two or more measurements showing
decreased activity at higher substrate concentrations). For the co-
factor,Vmax andKm values were fitted to aMM equation to get more
robust fits, and the Hill coefficients were obtained using nonlinear
regression with the Hill equation (Eq. 2).
v =
Vmax
1 +
Km
S
+
S
KSi
(1)
v =
VmaxSh
K hm + S
h
(2)
Thermal Stability of TH Activity
Wild type and mutant forms of TH were diluted in 10 μM Fe(II)
ammonium sulfate and 0.5 mg ml–1 BSA to 10 μM enzyme subunit
(0.56 mg ml–1), and incubated at 37°C, 45°C, and 55°C. Aliquots
were taken at different time points and assayed for remaining TH
activity as described above.
Oxygraphic Measurements
Oxygraphic assays of TH activities were carried out in a high-
resolution respirometer (Oroboros Oxygraph, Innsbruck, Austria)
[Gnaiger et al., 1995], essentially as described [Fossbakk andHaavik,
2005]. To reduce the background oxygen consumption, TH assay
was modified as follows. The concentrations of Fe(II), BH4, and
DTT was reduced to 4 μM, 125 μM, and 1.25 mM, respectively.
Dioxygen concentration was digitally recorded at time intervals of
2 sec. Reaction rates were calculated as the negative time deriva-
tives of dioxygen concentration and corrected for background from
instrument and autoxidation of the incubation medium contain-
ing substrates and cofactors without enzyme. Typical background
oxidation rate was 13.9 ± 2.6 pmol s–1 ml–1 at an initial oxygen
concentration of 240 μM.
Detection of Hydrogen Peroxide (H2O2)
An AmplexRed kit (InvitrogenTM) was used to quantify the
amount of H2O2 produced as a byproduct in the TH reaction.
The enzyme was incubated in 40 mM Na-HEPES pH 7.0, 50 μM
L-Tyr, 30μMBH4, and 1μMFe(II) ammonium sulfate for 4 min at
25°CbeforeAmplexRed reagentwas added. Further,we followed the
procedure described in the protocol provided by the manufacturer.
Molecular Modeling/Prediction Analysis
The protein structural model for the localization of the TH
variants was prepared based on the human TH X-ray diffraction
structure (PDB 2XSN, a truncated form of the enzyme lacking the
N-terminal first 192 residues and which was crystalized with a Zn2+
replacing the Fe2+ in the catalytic site). The active site of TH was
modeled using the structure of the catalytic domain of human PAH
with BH4 and 3-(2-thienyl)-L-alanine (PDB 1KW0) as template.
Accelrys Discovery Studio v3 1.1.11157 was used for the prepara-
tion of structural models. Predicted severity of the mutations were
estimated in MutPred (mutpred.mutdb.org) [Li et al., 2009]. FoldX
(v3.0; foldx.crg.es) [Schymkowitz et al., 2005] was used to estimate
the difference in protein stability (G) of the mutants relative to
wt-TH.
Results
Expression Efficiency and Solubility of wt and mutant TH in
E. coli
We here report for the first time a detailed characterization of
23 missense mutations in TH found in THD patients. An overview
of the nucleotide position of these and other THD mutations and
the position of the amino acids altered in the three-dimensional
structure of TH are shown in Figure 2. In addition, we include a
similar detailed characterization of seven THD mutations reported
in four previous studies (Fig. 2B, blue residues). Three promoter
variants (c.-69T>A, c.-70G>A, and c.-71C>T) and protein variants
(p.Gly294Arg, p.Gly315Ser, p.Ala385Val, and p.Gly408Arg) where
incomplete clinical data have been reported are also shown in Fig-
ure 2, but they have not been analyzed here. THmutations reported
after the start of the study [Chi et al., 2012; Stamelou et al., 2012;
Cai et al., 2013] were not analyzed biochemically.
Wild type and mutated forms of TH were produced without
fusion partners in E. coli, and soluble enzyme was purified by
Heparin Sepharose chromatography [Haavik et al., 1991]. Bacte-
ria were homogenized, and soluble and insoluble fractions were
analyzed with SDS-PAGE with Coomassie-blue staining. For the
wt TH, 43% of the protein appeared in the soluble fraction; how-
ever, the solubility of the THD mutants varied between 7% and
50% (Fig. 3A). The amount of soluble TH protein in the bacterial
lysates for the THmutants p.Cys207Tyr, p.Asp227Gly, p.Ala241Thr,
p.His246Tyr, p.Gly247Ser, p.Pro301Ala, p.Phe309Ser, p.Leu387Met,
p.Thr399Met, p.Gly414Arg, p.Gln459∗, and p.Ser467Gly was not
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Figure 2. Mutations in the TH gene. A: Schematic drawing of the genomic structure and location of mutations in human TH gene reported
by November 2013. Mutations without annotation are from Willemsen et al. (2010), and the mutations in bold are those studied here. Reference
sequence: NM_199292.2 (UniGene) transcript variant a (hTH4 with 528 amino acid). 1[Knappskog et al., 1995; Ludecke et al., 1996], 2[Royo et al.,
2005], 3[Calvo et al., 2010], 4 [Mak et al., 2010], 5[Stamelou et al., 2012], 6[Chi et al., 2012], 7[Giovanniello et al., 2012], 8[Cai et al., 2013]. B: Tetrameric
TH including the catalytic and tetramerization domains (left, PDB 1TOH) with one subunit detailed using human TH crystal structure (right, PDB
2XSN). All THD mutations expressed here for the first time are located in the catalytic and tetramerization domain (right amplification), and are
colored red, whereas mutations characterized by others [Knappskog et al., 1995; Ludecke et al., 1996; Royo et al., 2005; Calvo et al., 2010] are shown
in blue. The model was prepared using the software Accelrys Discovery Studio.
significantly different from wt TH. However, for the missense
variants p.Glu259Gly, p.Arg319Pro, p.Arg328Trp, p.Cys359Phe,
p.Phe375Leu, p.Ala376Val, p.Ile394Thr, p.Arg441Pro, p.Pro492Leu,
p.Asp498Gly, and p.Leu510Gln, the TH protein in the soluble frac-
tion was significantly reduced compared with wt TH (P < 0.05 or
<0.005, t-test) (Fig. 3A), where the mutants marked in bold showed
the largest decrease in solubility (four to sevenfold).
The solubility of TH in the bacterial extracts also affected the
amount of soluble enzyme that was recovered after partial purifi-
cation by heparin sepharose chromatography. Thus, the yield of
p.Cys207Tyr, p.His246Tyr, p.Gly247Ser, p.Cys359Phe, p.Phe375Leu,
p.Leu387Met, p.Thr399Met, p.Gly414Arg, p.Ser467Gly, and
p.Asp498Gly was similar (>50%) to that of wt TH. The TH
p.Asp227Gly, p.Ala241Thr, p.Pro301Ala, p.Phe309Ser, p.Pro492Leu,
p.Gln459∗, and p.Ile394Thr mutants had intermediate (10%–50%)
purification yield, whereas TH protein was hardly detectable for the
THmutants p.Arg328Trp, p.Arg441Pro, p.Glu259Gly, p.Arg319Pro,
p.Ala376Val, and p.Leu510Gln (Fig. 3B).
Thermal Stability
We next assessed the thermal stability of wt andmutated forms of
TH by estimating their first-order inactivation rate constant (kinact)
at 45°C, a measure of the kinetic stability of the enzymes (Fig. 3C).
For the TH mutants, p.Cys359Phe and p.Ser467Gly, we report kinact
constants measured at 37°C, as the rate at 45°C was too high to
be measured accurately. Interestingly, all mutants tested had sig-
nificantly higher rates of inactivation compared with wt TH (P <
0.05 or < 0.005, t-test). The most dramatic changes were found for
the TH mutants p.His246Tyr, p.Gly247Ser, and p.Ser467Gly where
kinact increased >threefold, whereas the p.Leu387Met mutant had a
twofold higher kinact.
Enzyme Activity and Kinetic Properties of wt and Mutated
Forms of TH
The enzymatic activity of wt andmutant THwas measured using
standardized in vitro assay conditions as described above. The TH
mutants p.Asp227Gly, p.Glu259Gly, p.Phe309Ser, p.Arg319Pro,
p.Arg328Trp, p.Ile394Thr, p.Arg441Pro, p.Gln459∗, p.Pro492Leu,
and p.Leu510Gln had no measurable enzyme activity (<0.2%
compared with wt TH) and were therefore not included in a
detailed study of their enzyme kinetic properties. Less than 20%
residual activity was found for TH mutants p.Cys207Tyr,
p.Ala241Thr, p.Pro301Ala, p.Cys359Phe, p.Phe375Leu,
p.Ala376Val, p.Thr399Met, p.Gly414Arg, p.Ser467Gly, and
p.Asp498Gly, whereas mutants p.His246Tyr, p.Gly247Ser, and
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Figure 3. Solubility and stability of the missense variants. A: The solubility of wt and mutant TH was compared. The fraction of soluble TH
(mean ± SD for N = 3–6) is given from measurements upon lysis of the bacteria (Materials and Methods). Protein in the soluble fraction of
mutant TH p.Cys207Tyr, p.Asp227Gly, p.Ala241Thr, p.His246Tyr, p.Gly247Ser, p.Pro301Ala, p.Phe309Ser, p.Leu387Met, p.Thr399Met, p.Gly414Arg,
p.Gln459∗, and p.Ser467Gly was not significantly different from wt TH. For mutant TH, p.Glu259Gly, p.Arg319Pro, p.Arg328Trp, p.Cys359Phe,
p.Phe375Leu, p.Ala376Val, p.Ile394Thr, p.Arg441Pro, p.Pro492Leu, p.Asp498Gly, and p.Leu510Gln protein in the soluble fraction was significantly
reduced compared with wt TH (∗P < 0.05 or ∗∗P < 0.005, t-test).B: Shows the protein yield of wt andmutant TH. Coomassie-blue SDS-PAGE gel (12%
acrylamide) showing total protein from E. coli lysates purified by Heparin Sepharose chromatography. Last lane showmolecular weight standards.
The position of TH protein is indicated (left) and the lanes are marked with enzyme variant. C: Compares the thermal inactivation rates of wt and
mutant forms of TH. The figure shows the rate of thermal inactivation as a measure of stability of wt TH and the mutants p.Cys207Tyr, p.His246Tyr,
p.Gly247Ser, p.Phe375Leu, p.Ala376Val, p.Leu387Met, p.Cys359Phe, and p.Ser467Gly. Enzyme activity was assayed as described in Methods after
incubation at 45°C or 37°C. Pure protein samples diluted in 10 μM Fe(II) ammonium sulfate and 0.5 mg ml BSA were incubated at 45°C or 37°C for
0–30 min. Aliquotes were assayed for TH activity at different time points and the rate constant of inactivation (kinact) was determined by fitting to
an exponential decay curve (Methods). Values are given as means ± SEM and represent data from three independent experiments. The rates of
inactivation of mutants TH p.Cys359Phe and p.Ser467Gly were too high at 45°C, and the values given in this figure were obtained at 37°C (right
panel). The stability of each of the mutants was significantly different from wt TH (∗P < 0.05, or ∗∗P < 0.005, t-test).
p.Leu387Met had 50%–100% activity compared with wt TH. All
mutants with measurable enzyme activity were investigated further
to determine their kinetic properties (Table 1).
Weobserveddifferences in all kinetic constants assessed.As shown
in Table 1, some of themutants had up to 16- and 1.4-fold increased
Km values for L-Tyr and BH4, respectively. However, the majority of
the THmutants had decreased Km values for BH4 and increased Km
values for tyrosine compared with wt TH. Themutants p.His246Tyr
and p.Gly247Ser had about 50% lower Vmax values, but only mod-
erately changed Km(Tyr), whereas they had increased affinity for
BH4 and had lost their negative cooperativity for the cofactor. To-
getherwithp.Leu387Met, they therefore hadno clear enzymekinetic
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Table 2. Amino Acid Substrate Specificity of wt TH and Selected Mutants
Protein (mutation) Substrate Vmax (nmol min
–1mg–1) Km (μM)
Vmax
Km
V
Tyr
maxK Phem
VPhemaxK
Tyr
m
V
Tyr
maxK DOPAm
VDOPAmax K
Tyr
m
wt TH L-Tyr 2460 ± 417 5.1 ± 2.2 484 88 114
L-Phe 1640 ± 148 296 ± 69 5.5
L-Dopa 126 ± 11 29.8 ± 8.5 4.2
p.Arg233His L-Tyr 150 ± 30 13.0 ± 4.0 11.5 4.8 7.7
(c.698A>G) L-Phe 352 ± 33 149 ± 22 2.4
L-Dopa 1.6 1.0 1.5
p.Gly247Ser L-Tyr 1189 ± 53 11.8 ± 0.9 101 16 36
(c.739G>A) L-Phe 734 ± 46 119 ± 25 6.2
L-Dopa 50 ± 9.4 17 ± 12 2.8
p.Cys359Phe L-Tyr 329.4 ± 4.2 37.6 ± 1.1 8.8 80
(c.1076G>T) L-Phe 73.2 ± 5.7 663 ± 99 0.1
L-Dopa n.m. n.m.
p.Phe375Leu L-Tyr 241 ± 20 56 ± 11 4.3 2.2 11
(c.1125C>G) L-Phe 1960 ± 44 993 ± 37 2.0
L-Dopa 77 ± 30 202 ± 135 0.4
p.Leu387Met L-Tyr 2830 ± 1450 24 ± 17 118 21 131
(c.1159C>A) L-Phe 1407 ± 78 258 ± 38 5.5
L-Dopa 62 ± 14 68 ± 39 0.9
p.Gly414Arg L-Tyr 66.8 ± 7.5 26.6 ± 8.1 2.5 0.5 1.3
(c.1240G>A) L-Phe 452 ± 17 92 ± 12 4.9
L-Dopa 35.1 ± 7.2 18 ± 13 1.9
The table summarizes the different enzyme kinetic parameters obtained for wt TH and some of the mutants, using L-Tyr, L-Phe, or L-Dopa as substrate. We did not observe
substrate inhibition kinetics for L-Phe or L-Dopa, which is why only Vmax and Km values are reported. The data for L-Tyr are taken from Table 1. Data points were fitted using
standard MM kinetics by nonlinear regression (Sigma plot) as described in Materials and Methods section. Values are given as the best estimate ± standard error of estimate.
n.m., not measured.
aberrancies that could explain their impaired enzyme function. In-
terestingly, several of the mutants showed no apparent substrate
inhibition with tyrosine (n.a. for Ksi[Tyr] in Table 1).
THD Mutants Show Altered Substrate Selectivity
In addition to the main physiological substrates tyrosine and
BH4, TH can utilize alternative amino acid substrates (Fig. 1) and
many synthetic BH4 derivatives [Teigen et al., 2004]. The alteredKm
values could indicate that somemutations affect the substrate bind-
ing sites in the enzyme, possibly also leading to altered substrate
specificity. To explore this possibility, the PAH and Dopa oxidase
activities were measured for enzyme variants that had relatively in-
tact catalytic activity and stability, but altered kinetic properties.
The mutant p.Arg233His characterized previously [Calvo et al.,
2010] was included in these experiments. As for the wt enzyme,
all TH variants tested also had significant PAH activities (Table 2).
The p.Phe375Leu mutant had in fact increased Vmax for phenylala-
nine along with a 10-fold decrease in its tyrosine hydroxylase ac-
tivity. However, this efficiency was moderated by an increase in the
Km value for both substrates, making the substrate specificity only
twofold different between tyrosine and phenylalanine. All mutants
except the p.Cys359Phe mutant had lost much of their substrate
selectivity, mainly driven by increased Km for tyrosine and lowered
Km for phenylalanine. The p.Gly414Arg mutant was in fact a more
efficient hydroxylase of phenylalanine than of tyrosine. The oppo-
site situation was found for the p.Cys359Phemutant, which had lost
more of its efficiency toward phenylalanine than for tyrosine.
L-Dopa has been shown to be a substrate for TH (Fig. 1), with
comparable Vmax and Km values as for tyrosine [Haavik, 1997]. The
TH-mediated oxidation of Dopa is thought to lead to the forma-
tion of neuromelanin and possibly to be involved inDopa-mediated
toxicity [Haavik and Toska, 1998]. The Dopa oxidase activity of wt
TH and 12 mutants with >2% residual TH activity was compared.
Under experimental conditions that were optimized for tyrosine
hydroxylation, the wt enzyme oxidized both substrates, but with a
Vmax/Km ratio for tyrosine that was more than 100-fold higher than
for L-Dopa. As shown in Table 2, p.Cys359Phe and to a lesser ex-
tent p.Leu387Met had increased selectivity for tyrosine over L-Dopa
compared with the wt, whereas the other mutants (p.Arg233His,
p.Gly247Ser, p.Phe375Leu, p.Leu387Met, and p.Gly414Arg) showed
lowered substrate selectivity. In particular, the pGly414Arg mutant
was a more efficient PAH than tyrosine hydroxylase and was ap-
proximately similarly efficient in oxidizing L-Dopa as tyrosine.
Oxygraphic Measurements and Coupling Efficiency
Suboptimal substrate binding could potentially also affect the
reaction stoichiometry and reaction coupling of TH. For the related
enzyme PAH and other oxidoreductases, some disease-associated
mutations show altered reaction stoichiometry with uncoupling of
substrate consumption to product formation [Kemsley et al., 2003].
Excess oxygen consumption in the enzyme reaction can lead to
the formation of reactive oxygen species (ROS) as side products.
To detect possible uncoupling of their hydroxylation reaction, all
mutant forms of TH studied here were screened for enzyme activity
using an oxygraphic assay [Fossbakk and Haavik, 2005]. For the TH
variants p.His246Tyr, p.Gly247Ser, p.Phe375Leu, p.Leu387Met, and
p.Ser467Gly that had high catalytic efficiency, we obtained high-
quality oxygraphic recordings of oxygen consumption during the
enzyme reaction. Samples were taken at fixed time intervals during
the reaction, and the formation of L-Dopa was measured by HPLC.
As previously described [Rostrup et al., 2008], the wt TH reaction
has a characteristic pattern of oxygen consumption with an initial
burst phase and a steady-state reaction rate after 1–2 min [Flatmark
et al., 1999]. This reaction pattern and the time courses for oxy-
gen consumption in the oxygraphic assay and L-Dopa production
(measured by HPLC) and coupling ratios were similar for wt TH
and the mutant TH variants that had measurable activity (Supp.
Fig. S1). To further investigate whether any of the mutants had
an impaired reaction coupling efficiency, resulting in the produc-
tion of ROS, we compared the production H2O2 by wt TH and 23
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mutant enzymes. However, we found no significant difference in
H2O2 production by these enzymes (data not shown).
Discussion
Inhumansamples sequenced so far, p.Val112Met appears tobe the
only common THmissense variant (frequency 0.418) [Ludecke and
Bartholome, 1995]. In contrast to this nonpathogenic amino acid
change in the regulatory domain, missense mutations reported in
THD are almost exclusively found in the catalytic or tetramerization
domains (Fig. 2). This also allowed us to purify the mutant proteins
using heparin sepharose, which relies on an intact heparin-binding
site in the N-terminal [Daubner and Piper, 1995]. Our characteriza-
tion of 23 of these mutants are in accordance with previous studies
of seven other variants of TH found in THD, that all show decreased
stability or activity compared with wt TH [Knappskog et al., 1995;
Ludecke et al., 1996; Royo et al., 2005; Calvo et al., 2010]. However,
various mutated forms of TH show great diversity in stability and
activity compared with wt TH (Table 3).
Mutations in the TH gene are expected to be relatively mild be-
cause severely reduced TH activity is not compatible with life. Mice
carrying TH null mutations (Th –/–), die in utero due to the failure
in the development of the cardiovascular system, but heterozygous
TH deficient mice have a normal life span [Zhou et al., 1995]. Re-
cently, a patient with early-onset PD was reported to have a rare
deletion of one entire TH allele and no mutation in the other allele.
This patient had no symptoms of disease from the catecholamin-
ergic system before PD was diagnosed at the age of 54, illustrating
that neurological symptoms of THD probably require >50% loss of
TH activity [Bademci et al., 2010]. THD is a phenotypically hetero-
geneous disease, and should be a differential diagnosis to consider
in patients with symptoms of PD. Furthermore, the authors asso-
ciated the rare deletion to the PD pathogenesis and the early onset
of disease [Bademci et al., 2010]. However, additional studies are
necessary to further investigate this matter (see also below).
The catalytic domain of the AAAHs is highly conserved among
species spanning from bacteria to mammals [Flydal and Martinez,
2013]. A model of the active site of human TH with bound L-Tyr
and BH4 was prepared based on the crystal structure of the catalytic
domain of human PAH complexed with BH4 and the substrate ana-
logue 3-(2-thienyl)-L-alanine (PDB 1KW0) [Andersen et al., 2002],
which aid to recognize the resides involved in the binding of the
pterin cofactor and of tyrosine in TH (Fig. 4). The catalytic cleft of
TH is about 17 A˚ deep with a ferrous iron 10 A˚ from the surface.
The iron is coordinated by two histidines and a glutamate (His-361,
His-366, and Glu-406; numeration in hTH4) (Fig. 4) [Goodwill
et al., 1997]. Asp-425 in rat TH (corresponding to Asp-455 in hTH4;
Fig. 4) has recently been shown to be a determinant for the substrate
specificity in TH, by critically avoiding hydrophophic interactions
that decrease the preference for L-Tyr without affecting the hydrox-
ylation of L-Phe [Daubner et al., 2013]. Although the ability of TH
to hydroxylate L-Phe in addition to L-Tyr could be considered an
advantage in phenylketonuria (PKU; MIM #261600) where there is
an excess of L-Phe and low availability of L-Tyr, the competitive na-
ture of these substrates could also compromise tyrosine hydroxylase
activity and catecholamine synthesis in this condition.
Of the mutants where we investigated the amino acid substrate
specificity (Table 2), p.Arg233His, p.Cys359Phe, p.Phe375Leu, and
p.Gly414Arg are mutations structurally positioned to affect active-
site residues (Fig. 4), and they only showed a moderately reduced
solubility and thermal stability (Table 3). We found a deleterious
kinetic effect for p.Arg233His, as previously reported [Calvo et al.,
Figure 4. A closer view of the active site of human TH. In green
are the iron coordinating triade (His361, His366, and Glu406) and the
BH4 binding Glu363 and Phe330. In blue are the substrate interacting
residues Arg346, Asp358, Pro357, Trp402, Phe330, and Asp455 (based
on the structure of the catalytic domain of human PAH with BH4 and
3-(2-thienyl)-L-alanine (PDB 1KW0)). Residues Arg233, Cys359, Phe375,
and Gly414 are shown in red.
2010], and in addition, a decrease in the relative preference for L-Tyr
as substrate compared with L-Phe and L-Dopa. Cys-359 is one of
the six conserved cysteines in TH. The mutation C359F is found
homozygous in an Italian boy with type B THD [Brautigam et al.,
1999]. As could be expected from the location of this mutation
in the substrate-binding site, p.Cys359Phe had a severely reduced
activity compared with wt TH (10%), and significantly altered
affinities for both tyrosine and the cofactor BH4. Interestingly, this
mutation led to a higher selectivity for L-Tyr. We also report large
kinetic aberrancies for p.Phe375Leu (10 or 43% Vmax compared
with wt TH), with decreased affinity for L-Tyr (Table 1). In a patient
with type B THD, this mutation was found in combination with
the C-terminal-located p.Ser467Gly mutation that had severely de-
creased stability. Interestingly, this patient had CSF HVA levels in
the low normal range prior to diagnosis, and still responded well to
treatment with low doses of L-Dopa [Clot et al., 2009; Doummar
et al., 2009].
Mutations closer to the C-terminal had severe effects on the
activity and in addition many of the mutations had decreased
solubility (as seen for TH p.Gly414Arg, p.Arg441Pro, p.Gln459∗,
p.Pro492Leu, p.Asp498Gly, and p.Leu510Gln). An exception was
TH p.Ser467Gly that had comparable solubility to wt TH, only
moderately reduced activity, but severely reduced thermal stability.
Together with p.His246Tyr and p.Gly247Ser, these are good candi-
dates for protein stabilization therapy as much of their catalytic ac-
tivities remained intact. Mutants that showed significant alterations
in solubility often also showed severely reduced activity. The TH
p.Phe375Leu and p.Ala376Val had significantly decreased solubility,
but it was not dramatically reduced and the mutants had consider-
able remaining activity and only slightly altered thermal inactivation
rates. Together with TH p.Leu387Met and p.Cys207Tyr, a combina-
tion of several negative effects, including cellular mechanisms not
addressed here, could be contributing to the pathogenic phenotype.
Active-site mutations in the AAAHs may interfere with normal
reaction mechanism, producing toxic by-products [Kemsley et al.,
2003]. Excess oxygen consumption in the TH reaction can lead to
the formation of ROS [Haavik et al., 1997]. Although we found
no evidence for this among the TH mutants studied here, it might
still be considered an additional pathogenic mechanism in vivo, as
proposed for PD [Haavik and Toska, 1998; Nakashima et al., 2013].
Within the family of the AAAHs, PAH is the most character-
ized enzyme with respect to the conformational and catalytic effects
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Table 3. Summary of Features of Mutant TH and Phenotypic Classification of Associated THD (Type A and B)
Mutation Type THD Solubility Residual activity Thermal stability Dominant feature MutPred predictiona Gb (kcal mol–1)
p.Cys207Tyrc A Moderately reduced <20% Moderately reduced Activity 0.790, –M∗, +P∗∗ 2.3:4.0
p.Asp227Glyc A Not reduced <0.2% n.d. Activity 0.960 6.6:6.7
p.Arg233Hisd A/B, homozygous 14% Moderately reduced Activity 0.980 2.6:2.5
p.Leu236Proe A/B, homozygous Reduced 16%f Activity 0.842, –S∗ 4.5:4.5
1.5% Activity
0.3% g Activity
p.Ala241Thrc A/B Moderately reduced <5% n.d. Activity 0.858 0.56:1.0
p.His246Tyrc A Not reduced >50% Severely reduced Stability 0.784 –0.35:–0.49
p.Gly247Serc A Not reduced <50% Severely reduced Stability 0.797, –C∗ 4.3:3.7
p.Glu259Glyc A Sign reduced n.d. n.d. Solubility/stability 0.816 5.3:5.0
p.Thr276Proh A – 100% Sign reduced Stability 0.845, –S∗ –0.19:–0.19
p.Pro301Alac B, homozygous Not reduced <5% n.d. Activity 0.892 2.6:2.6
p.Phe309Serc B, homozygous Moderately reduced <0.2% n.d. Activity 0.869, –S∗, +D∗∗ 4.3:4.1
p.Thr314Meth A – 24% Severely reduced Stability 0.956 4.5:4.6
p.Arg319Proc A Sign reduced <0.2% n.d. Solubility/stability 0.863, –M∗ 4.3:4.4
p.Arg328Trpc B Sign reduced <0.2% n.d. Solubility/stability 0.918, –M∗ 1.6:1.4
p.Arg337Hish A – 100% Severely reduced Stability 0.920 7.7:5.9
p.Cys359Phec B, homozygous Moderately reduced <10% Severely reduced Activity, stability 0.720 2.8:4.5
p.Phe375Leuc B Moderately reduced <10% Moderately reduced Activity 0.962 1.1:1.1
p.Ala376Valc A Sign reduced <10% Moderately reduced Solubility 0.972 1.9:1.8
p.Leu387Metc A Moderately reduced >50% Severely reduced Stability 0.881 0.58:0.65
p.Ile394Thrc A Sign reduced <0.2% n.d. Solubility/stability 0.817, +D∗, +P∗ , +U∗ 2.8:2.8
p.Thr399Metc B Moderately reduced <5% n.d. Activity 0.853 0.0:0.1
p.Gln412Lyse A, homozygous Reduced 18%f Activity 0.808, +M∗, +U∗ 0.33:0.45
65% Activity
p.Gly414Argc A Moderately reduced <10% n.d Activity, stability 0.844, –U∗ 1.8:1.9
p.Arg441Proc A Sign reduced <0.2% n.d. Solubility/stability 0.557 3.8:3.8
p.Gln459∗c B Moderately reduced <0.2% n.d. Activity - 0.87:0.82
p.Ser467Glyc A Not reduced <20% Severely reduced Thermal stability 0.901, –S∗, –D∗ 1.7:1.6
p.Pro492Leuc B Sign reduced <0.2% n.d. Solubility/stability 0.884 7.6:1.0
p.Thr494Meth A Sign reduced 100% Solubility 0.921 –0.25:–0.83
p.Asp498Glyc A Sign reduced <10% n.d. Activity, solubility/stability 0.840, –S∗ 2.7:1.3
p.Leu510Glnc A Sign reduced <0.2% n.d. Solubility/stability 0.801, +D∗ 2.3:0.2
aPredicted severity of the mutation was estimated in MutPred [mutpred.mutdb.org) [Li et al., 2009]. The numbers denote probability of deleterious/disease-associated mutation,
letters denote gain (+) or loss (-) of disorder (D), stability (S), catalytic activity (C), modification by methylation (M), by phosphorylation (P), or by ubiquitination (U), with
confidence P < 0.05 (∗) and P < 0.01 (∗∗). Modification need not be at the mutated residue.
bFoldX (v3.0; foldx.crg.es) [Schymkowitz et al., 2005] was used to estimate the difference in protein stability (G) of the mutants relative to wt TH. The crystal structure of
human TH (PDB: 2XSN) was used as template. Predictions were performed using both the tetrameric structure or a monomer of TH (G[tetramer]:G[monomer]). Values
are given pr. mol TH subunit. The greater the positive value, the larger is the predicted destabilization of TH by the mutation.
cThis work.
d[Calvo et al., 2010].
e[Knappskog et al., 1995], [Ludecke et al., 1996].
fProtein produced using a TNT in vitro translation system.
gProtein expressed in HEK293 cells.
h[Royo et al., 2005].
n.d., not determined.
of disease-associated mutations and genotype–phenotype relation-
ships [Muntau and Gersting, 2010; Blau et al., 2011]. The majority
(60%) of the approximately 850 mutations reported to date in
PAH found in hyperphenylalaninemia and PKU aremissensemuta-
tions (www.biopku.org/pah, accessed march 2014). As observed for
many other recessive genetic disorders, the predominant pathogenic
mechanism reduced stability or misfolding of mutated enzyme,
leading to loss of function [Pey et al., 2007; Scriver, 2007; Gerst-
ing et al., 2008]. Studies of both PAH and TPH1 and TPH2 have
shown that missense mutations in their catalytic and tetrameriza-
tion domains have a strong effect on the stability and activity of
the enzymes, whereas mutations in the regulatory domain have less
impact on these properties [Pey et al., 2007; McKinney et al., 2009].
N-terminalmutations in PAH are often associatedwith an increased
rate of aggregation for recombinantly expressed PAH variants [Pey
et al., 2004], but this is less obvious for TH. Different properties of a
partially unfolded intermediatemay explain these differenceswithin
the protein family [Kleppe et al., 1999; Kleppe and Haavik, 2004],
and why TH is not as sensitive to mutations in its N-terminal do-
main [Kleppe and Haavik, 2004]. Although THD is a rare disorder,
with less than 70 patients being reported so far, it can be considered
a model disease for the group of neurogenetic disorders affecting
monoaminergic neurotransmission. Thus, the residual TH biosyn-
thetic capacity is related to symptom severity (Fig. 5). It has also
been proposed that TH contributes to the progressive degeneration
of dopaminergic neurons [Haavik et al., 1997; Haavik and Toska,
1998]. Although THD in general does not seem to be associated
with neurodegeneration, the recent discovery of THD precludes a
clear assumption about a possible dopaminergic degeneration with
progressive neurological deficits in these patients and whether this
may be related to certain TH genotypes. The biochemical charac-
terization performed here could help identifying TH variants that
have a higher risk of causing cellular damage.
Whether it is caused by primary THD or by degeneration of
catecholaminergic neurons, as found in sporadic or familial PD,
dopamine deficiency is usually treated with administration of Dopa
or dopamine agonists. High levels of Dopa can even be neuro-
toxic and be oxidized to reactive intermediates, including quinones,
semiquinones, and hydrogen peroxide [Kostrzewa et al., 2002].
Thus, it has been speculated whether oxidation of Dopa by TH
can contribute to the progressive degeneration of dopaminergic
neurons found in PD [Haavik et al., 1997; Haavik and Toska, 1998].
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Figure 5. Mutations found in THD type B patients showed lower
activity. The average remaining activity in mutations found in patients
classified in THD subtypes A (N = 19 patients) and B (N = 10 patients)
[Willemsen et al., 2010] were significantly different (∗P < 0.05, t-test).
Possibly, the relatively increased efficacy of Dopa as substrate for
p.Arg233His, p.Gly247Ser, p.Phe375Leu, and p.Gly414Arg may be a
risk factor for a progressive course of neurological symptoms in pa-
tients harboring this mutation. As the role of TH in the generation
of neuromelanin and Dopa oxidation in vivo is not settled, the role
of the mutants in the production of this pigment is not clear. The in
vitro TH assays were performed with 200 μMBH4, which probably
is much higher than the physiological levels. Thus, Dopa may be a
relatively better substrate for TH in vivo, as the enzyme has a higher
cofactor affinity for the L-Dopa oxidase reaction than for tyrosine
hydroxylation [Haavik et al., 1997].
In vitro studies of mutant proteins give important information
about structural and mechanistic changes caused by a mutation.
However, these studies do not provide a complete picture of how
mutations affect proteins in vivo. Thus, mutations could also inter-
fere with TH regulation, interaction with other proteins, chaperone
interaction, or proteolytic degradation in cells. Mutations can also
interfere with mRNA synthesis, stability, localization, or splicing
[Chen and Miller, 2008]. Thus, further information could have
been obtained if the mutants had been stably expressed in post-
mitotic human dopaminergic neurons. Despite these limitations,
in vitro studies reported here are essential for understanding the
molecular mechanisms of disease-causing mutations.
Genotype–Phenotype Correlations
A clear correlation between genotype and phenotype in THD
has not been established. The establishment of such a correlation is
complicated by the small number of patients reported, and that the
majority of patients are compound heterozygous for mutations in
the TH gene. Homozygosity of the p.Arg233His mutation is found
in six type A and three type B patients. The p.Leu236Pro mutation
occurred homozygously in one type A and two type B patients.
However, all patients with at least one promoter mutation had the
type A THD [Willemsen et al., 2010], indicating that some TH pro-
tein was produced despite the presence of the promoter mutation.
In THD patients born of related parents, there is also an increased
risk of other autosomal-recessive traits/diseases that can complicate
the clinical symptoms. There is nevertheless a correlation between
some biochemical markers, such as CSFHVA levels, and the severity
of their THD symptoms [Willemsen et al., 2010]. Here, we observed
a poor correlation between the remaining activity of the TH mu-
tants and CSF HVA content of the patients for which this parameter
was available (data not shown). This is not unexpected, as CSFHVA
values are highly dependent on the age of the subjects, and the as-
say protocols that have been used. Interestingly, the clinical subtype
(type A or B) of the THD patients could be predicted based on
measurements of the in vitro TH activity (Fig. 5).
Future Perspectives
As treatment of THD and Parkinson’s disease with L-Dopa or
dopamine agonists often is inadequate and may only provide tem-
porary symptom relief, searches for treatments that directly tar-
get the malfunctioning TH are being conducted. Pharmacological
chaperones are compounds that can stabilize the natural protein
conformation and protect against denaturation. The cofactor BH4
can actually act as a chaperone when supplemented pharmacologi-
cally, stabilizing TH in vivo [Thony et al., 2008]. It has been reported
that synthetic pharmacological chaperones can stabilize the human
TH mutant p.Arg202His (corresponding to p.Arg233His in TH4)
in vitro [Calvo et al., 2010]. Based on the characterization per-
formed here, p.His246Tyr, p.Gly247Ser, p.Leu387Met, p.Ser467Gly,
and possibly p.Cys359Phe are good candidates for targeting by phar-
macological chaperones as they retained activity and solubility, but
had increased thermal inactivation rates. In conclusion, this study
provides new insights to the mechanism of pathogenesis of muta-
tions inTH that canbeused in the search for new, targeted treatment
strategies, and to find stabilizing compounds that may reverse the
negative effects of the mutations on the enzyme activity.
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